Explore
Upload

DocSlides is a free service to upload presentations and documents.

Upload Now

Search Results for 'Ibrutinib'

Ibrutinib published presentations and documents on DocSlides.

Mechanisms of

Mechanisms of

  • giovanna-bartolotta
  • 42 Slides

Ibrutinib. Sensitivity and Resistance in CLL. Y....

Mantelcell

Mantelcell

  • tawny-fly
  • 44 Slides

. lymfom. Från. indolent till aggressive . sju...

Chronic lymphocytic leukemia,

Chronic lymphocytic leukemia,

  • natalia-silvester
  • 31 Slides

New agents timing?. Agne Paner, MD. Assistant pro...

Randomized Comparison of Ibrutinib Versus Ofatumumab in Rel

Randomized Comparison of Ibrutinib Versus Ofatumumab in Rel

  • jane-oiler
  • 19 Slides

Presented By John Byrd at 2014 ASCO Annual Meetin...

Ibrutinib: Analysis of Pivotal Data

Ibrutinib: Analysis of Pivotal Data

  • alida-meadow
  • 32 Slides

Richard R. Furman, MD. CLL Research Center. BCR-a...

Randomized Phase III

Randomized Phase III

  • marina-yarberry
  • 20 Slides

RESONATE . (PCYC-1112) Trial of Ibrutinib Compare...

Integration of Novel Therapies in WM and CLL : When and How

Integration of Novel Therapies in WM and CLL : When and How

  • giovanna-bartolotta
  • 55 Slides

Neil E Kay, M.D.. October 2014. Mayo Team. Deb Bo...

BTK Inhibitors and Cardiac Considerations in Chronic Lymphocytic Leukemia

BTK Inhibitors and Cardiac Considerations in Chronic Lymphocytic Leukemia

  • tawny-fly
  • 0 Slides

Overview. Overview (cont). Ibrutinib. -R. elated ...

Ibrutinib for Hairy Cell Leukemia

Ibrutinib for Hairy Cell Leukemia

  • pasty-toler
  • 0 Slides

. A Brief Update of an Ongoing Trial. Jeff Jones...

Ibrutinib : First-in Class Inhibitor of BTK

Ibrutinib : First-in Class Inhibitor of BTK

  • briana-ranney
  • 0 Slides

Forms a specific and irreversible bond with cyste...

Btk inhibition in Mantle cell Lymphoma & CLL

Btk inhibition in Mantle cell Lymphoma & CLL

  • test
  • 0 Slides

Simon Rule. Professor of Clinical . Haematology. ...

Updates in Lymphoma From Recent Congresses

Updates in Lymphoma From Recent Congresses

  • lindy-dunigan
  • 0 Slides

Therapeutic Targets in CLL. Venetoclax in Patient...

Pharmacist Focus on BTK Inhibitors Moderator Shilpa Paul, PharmD, BCOP

Pharmacist Focus on BTK Inhibitors Moderator Shilpa Paul, PharmD, BCOP

  • ellena-manuel
  • 25 Slides

Pharmacist Focus on BTK Inhibitors Moderator Shil...

CLL Stromal cell protect

CLL Stromal cell protect

  • tawny-fly
  • 20 Slides

CLL Stromal cell protect Conventional therapies V...

Overall Survival Benefit of

Overall Survival Benefit of

  • tatyana-admore
  • 123 Slides

Obinutuzumab. Over Rituximab when Combined with ...

2022 Spring Oncology Conference

2022 Spring Oncology Conference

  • byrne
  • 62 Slides

Evolving Treatment Strategies. for CLL/SLL and MCL...

First Prospective Data on Minimal Residual Disease (MRD) Outcomes After Fixed-Duration Ibrutinib P

First Prospective Data on Minimal Residual Disease (MRD) Outcomes After Fixed-Duration Ibrutinib P

  • mia
  • 23 Slides

Ibr+Ven. ) Versus Chlorambucil Plus Obinutuzumab (...

Module 3: Chronic Lymphocytic Leukemia

Module 3: Chronic Lymphocytic Leukemia

  • CottonTails
  • 26 Slides

Josie . Montegaard. , MSN, AGPCNP-BC. Matthew S . ...

uidelines

uidelines

  • stella
  • 25 Slides

Pan - London Haemato - O ncology Clinical G Lymph...

Research To Practice ASH 2022 CLL Updates

Research To Practice ASH 2022 CLL Updates

  • erica
  • 30 Slides

John N. Allan. Associate Professor of Clinical Med...

CLL: clinical cases Celso Arrais

CLL: clinical cases Celso Arrais

  • genevieve
  • 36 Slides

Conflict of Interests. I declare NO relevant confl...

Prevalence of BTK and

Prevalence of BTK and

  • kareem342
  • 6 Slides

PLCG2. Mutations in CLL Patients relapsing under ...

Copyright © 2024 DocSlides. All Rights Reserved